Ariad Pharmaceuticals clinical trials

Acquired by Takeda, Feb 16, 2017 · source ↗

The registry lists 13 studies whose lead sponsor is Ariad Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 31, 2025.

Studies

Recruiting first, then most recently updated. Showing 13 of 13. All Takeda studies →

• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibCompletedNCT03535740Phase 2

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted after Ariad Pharmaceuticals became part of Takeda

• An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®TerminatedNCT02455024

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01667133Phase 1/2

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid LeukemiaTerminatedNCT02627677Phase 3

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)CompletedNCT01449461Phase 1/2

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02094573Phase 2

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT01207440Phase 2

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorCompletedNCT01874665Phase 2

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological MalignanciesCompletedNCT00660920Phase 1

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT02784158

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• Expanded Access Program of PonatinibApproved for marketingNCT01592136

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda

• Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)TerminatedNCT01650805Phase 3

  Sponsor listed in the registry: Ariad Pharmaceuticals · First submitted before Ariad Pharmaceuticals became part of Takeda